Oxis Biotech Executes Amended Option Agreement With the University of Pittsburgh
TAMPA, FL -- (Marketwired) -- 08/04/15 -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. (OTCQB: OXIS) and (EURONEXT PARIS: OXI.PA) announced today the execution of the amendment to its current exclusive option agreement with the University of Pittsburgh related to certain patent rights developed by Dr. Xiang-Qun Xie, Associate Dean for Research Innovation and Professor, Pharmaceutical Sciences, School of Pharmacy. The patent rights relate to the addition of certain novel compositions-of-matter which could prove useful as therapeutics for the treatment of various human diseases.
"We are pleased to have the opportunity to expand our current relationship with the University of Pittsburgh," said Anthony J. Cataldo, Chairman and CEO of Oxis Biotech.
The novel p62 inhibitors developed by Dr. Xie and his colleagues at the University of Pittsburgh demonstrate inhibition of multiple myeloma cell growth without toxicity to normal bone marrow stromal cells. Bone marrow stromal cells are involved in hematopoiesis and certain inflammatory processes.
Multiple myeloma is a type of cancer that forms in white blood cells, and affects about 26,850 people annually in the USA causing about 11,240 deaths per year. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Multiple myeloma is also characterized by destructive osteolytic bone lesions (rounded, punched-out areas of bone), diffuse osteoporosis, bone pain, and the production of abnormal proteins which accumulate in the urine. Plasma cell leukemia, a condition in which plasma cells comprise greater than 20% of peripheral leukocytes, is typically a terminal stage of multiple myeloma and is associated with short survival.
Multiple myeloma is marked by abnormal protein production, and frequently is characterized by bone disease - a major cause of patient morbidity. Multiple myeloma induced bone disease is marked by holes in the bone and intense pain due to increased osteoclast bone degradation activity and highly suppressed or absent osteoblast bone remodeling (growth) activity. Cell adhesive interactions between multiple myeloma cells and bone marrow stromal cells activate multiple signaling pathways that enhance cancerous tumor growth and bone destruction while suppressing new bone formation and contributing to drug resistance.
The recent improvements in overall survival and remission duration in multiple myeloma are largely due to the advent of novel therapeutic agents. These therapeutic agents exploit a tumor cell's dependency on clearance mechanisms for abnormal or mutant cellular proteins. Tumor cells are very sensitive to any type of inhibition of this clearance mechanism which when inhibited leads to an antiproliferative and pro-apoptotic effect on the tumor cells mediated by induction of endoplasmic reticulum stress, activation of caspases, and generation of reactive oxygen species.
p62 is a protein having multiple biological roles involving cell signaling, cell receptor internalization, and protein degradation/turnover. p62 has been reported to be a regulator of inflammation, neurogenesis, increased osteoclastogenesis (bone destruction), adipogenesis and T-cell differentiation. One of the more interesting functions of p62 is the regulation of NF-kappa-B, which is the master regulator of innate immunity and aging. p62 is also found in inclusion bodies containing polyubiquitinated protein aggregates which are present in several neurodegenerative diseases such as Parkinson, Alzheimer, and Huntington's diseases. Additionally, p62 acts as s shuttling factor for the delivery of damaged biomolecules to the proteasome for destruction and removal.
By selectively inhibiting p62 in multiple myeloma cancer cells, stress is induced in the multiple myeloma cancer cells due to the accumulation within the cells of damaged biomolecules that cannot be destroyed via the normal function of the proteasome. As a result of the stress placed on the cancer cells by inhibition of p62, the cancer cells undergo a biological process known as autophagy which results in their destruction.
OXS-4235 is a first-in-class therapeutic candidate targeting the inhibition of p62 for the treatment of multiple myeloma and osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma tumors, decrease osteolytic lesions, and the ability to help restore normal bone remodeling resulting in healthy bone. In addition to direct killing of multiple myeloma cells, OXS-4235 was found to also inhibit TNF-alpha mediated osteoclast formation. TNF-alpha is a major suppressor of osteoblast differentiation. TNF-alpha is upregulated in the bone marrow microenvironment resulting from multiple myeloma cell - stromal cell interactions. Reducing osteoblast suppression in the multiple myeloma bone marrow microenvironment via the inhibition of TNF-alpha, normal bone remodeling is restored. "OXS-4235's dual mechanism of action, and no observed toxicity in mouse models of multiple myeloma is very exciting", stated Anthony Cataldo, Chairman and Chief Executive Officer of Oxis Biotech, Inc.
About Oxis Biotech, Inc.
Oxis Biotech develops innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. For more information about Oxis Biotech, please visit http://www.oxis.com.
About the University of Pittsburgh School of Pharmacy
Chartered in 1878, the School of Pharmacy is the oldest of the University of Pittsburgh's Schools of the Health Sciences, and is ranked in the top 10 nationwide. The School of Pharmacy is on the forefront of educating future practitioners with its four-year Pharm. D. program, and is a leader in research with endeavors ranging from patient care outcomes and human clinical research to research in molecular genetics. Like the other Schools of the Health Sciences, the School of Pharmacy is also affiliated with the internationally renowned University of Pittsburgh Medical Center (UPMC) which provides the region's largest network of tertiary, specialty, and community hospitals. Collectively, these facilities provide one of the nation's most complete health centers for teaching, patient care, and research in the health sciences. For more information about the School of Pharmacy, please visit http://www.pharmacy.pitt.edu.
Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
Oxis Biotech, Inc.
Investor Relations
800-304-9888
Source: Oxis International, Inc.
Released August 4, 2015